Disease · MP_0001914

hemorrhage

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hemorrhage. Diseases, record MP_0001914. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MP_0001914

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hemorrhage; Open Targets
Open Targets ID: MP_0001914; Open Targets
Other names: bleeding, haemorrhage; Open Targets
MeSH: D006470; MeSH
NCI Thesaurus: C26791; NCI Thesaurus
Highest stage of its drugs: Approval, for 72 of its 139 drugs, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs139

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TRANEXAMIC ACID	CHEMBL877	Small molecule	Approval	ATC and DailyMed	65	50	50	Drugs and targets
FIBRINOGEN, HUMAN	CHEMBL2109072		Approval	ATC	10	9	6	Drugs and targets
EPINEPHRINE	CHEMBL679	Small molecule	Approval	ATC	7	6	6	Drugs and targets
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Approval	DailyMed	9	4	4	Drugs and targets
THROMBIN	CHEMBL2108110		Approval	ATC	6	4	4	Drugs and targets
AMINOCAPROIC ACID	CHEMBL1046	Small molecule	Approval	ATC and DailyMed	11	3	3	Drugs and targets
MISOPROSTOL	CHEMBL606	Small molecule	Approval	DailyMed	16	2	2	Drugs and targets
DESMOPRESSIN ACETATE	CHEMBL1200556	Protein	Approval	DailyMed	8	2	2	Drugs and targets
MEDROXYPROGESTERONE ACETATE	CHEMBL717	Small molecule	Approval	DailyMed	4	2	2	Drugs and targets
LEVONORGESTREL	CHEMBL1389	Small molecule	Approval	DailyMed	3	2	1	Drugs and targets

1 to 10 of 139

See all 139 drugs

Targets95

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
F8	Coagulation factor VIII	9	Coagulation factor VIII exogenous protein	Approval	https://conductscience.org/library/genes/2157	Drugs and targets
F9	Coagulation factor IX	9	Coagulation factor IX and X other; Coagulation factor IX exogenous gene; Coagulation factor IX exogenous protein	Approval	https://conductscience.org/library/genes/2158	Drugs and targets
F10	Coagulation factor IX and X	7	Coagulation factor IX and X other; Coagulation factor X exogenous protein; Coagulation factor X inhibitor	Approval	https://conductscience.org/library/genes/2159	Drugs and targets
PGR	Progesterone receptor	6	Progesterone receptor agonist	Approval	https://conductscience.org/library/genes/5241	Drugs and targets
PTGS2	Cyclooxygenase	6	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
SERPINC1	Antithrombin-III	6	Antithrombin-III activator	Phase 3	https://conductscience.org/library/genes/462	Drugs and targets
PTGS1	Cyclooxygenase	5	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
MPL	Thrombopoietin receptor	4	Thrombopoietin receptor agonist	Approval	https://conductscience.org/library/genes/4352	Drugs and targets
AVPR1A	Vasopressin V1 receptor	3	Vasopressin V1 receptor binding agent; Vasopressin receptor agonist	Approval	https://conductscience.org/library/genes/552	Drugs and targets
AVPR1B	Vasopressin V1 receptor	3	Vasopressin V1 receptor binding agent; Vasopressin receptor agonist	Approval	https://conductscience.org/library/genes/553	Drugs and targets

1 to 10 of 95

See all 95 targets

Trials138

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01064362	Hemorrhage Risk Prescribed Arixtra		13,442	2011-02-11	Thrombosis, Venous	DALTEPARIN SODIUM, ENOXAPARIN, ENOXAPARIN SODIUM, FONDAPARINUX SODIUM, NADROPARIN CALCIUM, TINZAPARIN	Its record names the disease	ClinicalTrials.gov
NCT02086500	Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial)	Phase 3	903	2020-09-10	Traumatic Hemorrhage	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00113568	Safety Study of XP12B in Women With Menorrhagia	Phase 3	784	2010-01-20	Menorrhagia, Heavy Menstrual Bleeding	TRANEXAMIC ACID	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01940523	Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical	Phase 4	640	2017-06-14	Osteoarthritis	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00784134	Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III	Phase 3	500	2017-07-02	Intraventricular Hemorrhage	ALTEPLASE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03412890	LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	Phase 3	477	2024-05-09	Heavy Menstrual Bleeding, Uterine Fibroid	ESTRADIOL, NORETHINDRONE ACETATE, RELUGOLIX	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02925494	An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	Phase 3	433	2020-06-30	Uterine Fibroids, Heavy Menstrual Bleeding	ELAGOLIX, ESTRADIOL, NORETHINDRONE ACETATE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT05523297	Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery	Phase 3	420	2025-08-15	Bleeding Cardiac Surgery Patients	PROTHROMBIN COMPLEX CONCENTRATE	Its record names the disease	ClinicalTrials.gov
NCT02654054	Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women	Phase 3	413	2020-06-29	Uterine Fibroids, Heavy Menstrual Bleeding	ELAGOLIX, ESTRADIOL, NORETHINDRONE ACETATE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04089865	Oral Versus Intravenous Tranexamic Acid	Phase 4	400	2023-06-01	Blood Loss, Blood Transfusion	TRANEXAMIC ACID	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 138

See all 138 trials

Comparisons in its trials86

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Prehospital Tranexamic Acid vs Control: deaths from any cause	36 of 447	45 of 456	903	NCT02086500	Trial comparisons
Prehospital Tranexamic Acid vs Control: serious adverse events	4 of 447	7 of 456	903	NCT02086500	Trial comparisons
Prehospital Tranexamic Acid vs Control: Multiple Organ Failure	33 of 447	39 of 453	900	NCT02086500	Trial comparisons
Prehospital Tranexamic Acid vs Control: 24 Hour Mortality	16 of 447	17 of 453	900	NCT02086500	Trial comparisons
Prehospital Tranexamic Acid vs Control: Hyperfinbrinolysis	145 of 447	144 of 453	900	NCT02086500	Trial comparisons
Prehospital Tranexamic Acid vs Control: Acute Lung Injury	42 of 447	39 of 453	900	NCT02086500	Trial comparisons
Prehospital Tranexamic Acid vs Control: Nosocomial Infection	88 of 447	66 of 453	900	NCT02086500	Trial comparisons
Prehospital Tranexamic Acid vs Control: 30 Day Mortality	36 of 442	45 of 452	894	NCT02086500	Trial comparisons
IV TXA Group vs Topical TXA Group: The Number Patients Requiring a Transfusion	2 of 320	6 of 320	640	NCT01940523	Trial comparisons
Topical Tranexamic Acid vs Intravenous Tranexamic Acid: serious adverse events	0 of 320	0 of 320	640	NCT01940523	Trial comparisons

1 to 10 of 86

See all 86 comparisons in its trials

Papers from its trials152

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39022429	RESULT	1	PubMed
37592715	RESULT	1	PubMed
36952300	RESULT	1	PubMed
33939696	RESULT	1	PubMed
32869124	RESULT	1	PubMed
32862267	RESULT	1	PubMed
32766393	RESULT	1	PubMed
32253548	RESULT	1	PubMed
32209286	RESULT	1	PubMed
32045513	RESULT	1	PubMed

1 to 10 of 152

See all 152 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MP_0001914

GET https://conductscience.org/api/diseases/v1/MP_0001914/drugs?page=2

API reference For AI assistants